Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Impact of DNA Repair Pathway Alterations Identified by Circulating Tumor DNA on Sensitivity to Radium-223 in Bone Metastatic Castration-Resistant Prostate Cancer

NCT04489719 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT04489719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04489719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Impact of DNA Repair Pathway Alterations Identified by Circulating Tumor DNA on Sensitivity to Radium-223 in Bone Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
University of Washington
Phase
Observational
Overall status
Recruiting
Start date
April 16, 2021
Completion date
August 1, 2030
Enrollment
48 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate carcinoma, metastatic malignant neoplasm in the bone, metastatic prostate carcinoma, stage ivb prostate cancer ajcc v8